Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes a case where a patient with alopecia totalis treated with the JAK inhibitor tofacitinib showed hair regrowth but experienced worsened facial acne.

This case report discusses the use of a prostaglandin analogue for treating eyebrow loss in a patient with frontal fibrosing alopecia, but provides no new clinical results.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

This study found a strong dose-related increase in the risk of intracranial meningiomas associated with high doses of cyproterone acetate, with some reduction in risk after stopping the treatment.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

Adding zinc to pyrithione zinc improves its effectiveness against scalp conditions like dandruff.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

This abstract reviews the management of polycystic ovary syndrome and highlights the potential benefits of lifestyle changes over metformin in reducing type 2 diabetes risk, yet reports no new clinical outcomes.

This study found that flutamide, finasteride, ketoconazole, and EE-CPA all significantly reduced hirsutism scores, hair diameter, and hair growth rate in women with hirsutism over 12 months.

This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.

This case report describes the first known instance of fixed drug eruption linked to finasteride, confirmed through an oral challenge test that reproduced symptoms at the same skin site.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.

This study observed that tofacitinib therapy over about 16 weeks had a positive effect in children with alopecia areata, reducing the SALT index significantly in some patients.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

This study found that both finasteride and flutamide significantly decreased hirsutism severity and hair diameter in women with PCOS and Idiopathic Hirsutism, with abdominal hairs showing greater sensitivity to the treatments.

In this observational study, treatment with oral isotretinoin was reported to stabilize hair loss in patients with frontal fibrosing alopecia, offering potential guidance for clinicians on its therapeutic use, with implications for improving affected patients' self-esteem.

In this case study, researchers reported that a patient with plaque alopecia areata experienced complete and sustained hair regrowth after treatment with 5-Fluorouracil and Bleomycin via microinfusion of medicines, despite initial cutaneous atrophy caused by intralesional corticosteroid therapy.

This study found that Puerariae Flos extract inhibited testosterone 5α-reductase and promoted hair growth in mouse models, suggesting its potential use for treating androgenic alopecia.

This erratum addresses the long-term effects of finasteride on prostate-specific antigen levels but reports no new research findings.

This review discusses the pharmacological properties and clinical applications of cyproterone acetate and similar antiandrogens, noting previous failures in local applications due to concentration limitations; it reports no new empirical results.

This study found that in patients with frontal fibrosing alopecia, combining topical tacrolimus with isotretinoin is more effective after four weeks of treatment compared to tacrolimus with finasteride, though both regimens offered some benefit.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

This study developed a novel method to simultaneously measure finasteride, dutasteride, and related biomarkers in serum, finding that both drugs lowered DHT levels while increasing substrate concentrations.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.